Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase domain 20 pseudogene 2 (ADAM20P2) is a pseudogene related to the ADAM (A Disintegrin And Metalloproteinase) family, named for its sequence similarity to ADAM20. Pseudogenes like ADAM20P2 are genomic DNA sequences similar to normal genes but are non-functional; they do not encode a functional protein due to disruptions such as insertions, deletions, or premature stop codons[3]. There is no evidence that ADAM20P2 produces a functional protein product, contributes to canonical ADAM family activities (such as cell adhesion or proteolysis), or plays a direct role in human disease or therapeutic targeting. The ADAM family itself is known for membrane-anchored proteins involved in proteolysis and cell signaling, but ADAM20P2 does not code for such a protein[1][3]. This entry is a pseudogene and therefore is not an active protein or typical drug target (enzyme, receptor, etc.), and its inclusion as a therapeutic target is usually incorrect[3]. No drug interactions, mechanisms of action, biomarker status, or safety concerns have been associated with this sequence[3]. If you need information on the closely related functional gene/protein ADAM20, which does encode a metalloprotease and participates in cell adhesion and proteolysis, please clarify, as ADAM20P2 specifically is a pseudogene and not a protein-coding therapeutic target[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain 20 pseudogene 2 (ADAM20P2).